載入中
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
前收盤價
US$78.96
−US$5.02 · -5.98%
盤中時間採用ET。市場資料可能有所延遲。
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
日內區間
目前US$78.96
52週區間
目前US$78.96
盤中時間採用ET。市場資料可能有所延遲。
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
日內區間
目前US$78.96
52週區間
目前US$78.96
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 99.04億 USD | 1300.6萬 USD | 560.02萬 USD | 759.16萬 USD | 649.32萬 USD |
| 銷售、一般及管理費用 | 68億 USD | 315.57萬 USD | 323.1萬 USD | 294.53萬 USD | 263.4萬 USD |
| 營業費用 | 1670.44萬 USD | 1616.17萬 USD | 883.12萬 USD | 1053.69萬 USD | 912.72萬 USD |
| 利息收入 | 298.75萬 USD | 40.4萬 USD | 42.9萬 USD | 2.12萬 USD | 2.4萬 USD |
| 營業利益 | −1670.44萬 USD | −1616.17萬 USD | −883.12萬 USD | −1053.69萬 USD | −912.72萬 USD |
| 淨利 | −1371.69萬 USD | −1558.64萬 USD | −840.22萬 USD | −1051.56萬 USD | −910.32萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$126
上漲空間 59.57%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1788.48萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1168.43萬0.12%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1020.94萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF511.11萬0.01%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO290.32萬0.02%180億 USD0.06%US$112.66+0.50%
Vanguard U.S. Momentum Factor ETFVFMO169.9萬0.08%19億 USD0.13%US$230.11+1.02%
iShares Micro-Cap ETFIWC119.87萬0.09%13.17億 USD0.60%US$183+0.11%
iShares Core S&P Total U.S. Stock Market ETFITOT97.92萬0.00%980.88億 USD0.03%US$169.66+0.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOVanguard U.S. Momentum Factor ETFVFMOiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
